Skip to search formSkip to main contentSkip to account menu

flibanserin

Known as: 1-(2-(4-(3-trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

AddyiBIMT-17

Broader (1)

Benzimidazoles
flibanserin 100 MG Oral Tablet [Addyi]

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Mass spectrometry based rapid quantitative bioanalysis of flibanserin; pharmacokinetic and brain tissue distribution study.
Flibanserin (FLB) is the first USFDA approved serotonin modulator recently marketed to treat acquired generalized women… 
2018
2018
Flibanserin toxicity in a toddler following ingestion
Abstract Introduction: Flibanserin is a medication recently approved by the FDA for treatment of generalized hypoactive sexual… 
Review
2017
Review
2017
Flibanserin and its discontents
In August 2015, flibanserin (brand name Addyi) was approved by the Food and Drug Administration (FDA) for treatment of acquired… 
2016
2016
Retinal Neuroprotective Effects of Flibanserin, an FDA-Approved Dual Serotonin Receptor Agonist-Antagonist
Purpose To assess the neuroprotective effects of flibanserin (formerly BIMT-17), a dual 5-HT1A agonist and 5-HT2A antagonist, in… 
2011
2011
Flibanserin attenuates l-DOPA-sensitized contraversive circling in the unilaterally 6-hydroxydopamine-lesioned rat model of Parkinson’s disease
A central problem in the treatment of Parkinson’s disease (PD) is the development of motor disturbances like l-DOPA-induced… 
2001
2001
Lack of interaction between flibanserin and antidepressants in inducing serotonergic syndrome in rats.
This study was aimed at evaluating the ability of flibanserin, a 5-HT1A receptor full agonist with antidepressant potential, to… 
2001
2001
Further characterisation of potential antidepressant action of flibanserin
Abstract Rationale: Flibanserin has shown antidepressant-like properties in some animal models. In order to better define the… 
2000
2000
Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety
This study compared the effects of flibanserin, a novel 5‐HT1A agonist/5‐HT2A antagonist; diazepam, a traditional anxiolytic; and… 
1999
1999
Behavioral Effects of Flibanserin (BIMT 17)
1998
1998
In vivo electrophysiological assessment of the agonistic properties of flibanserin at pre‐ and postsynaptic 5‐HT1A receptors in the rat brain
Flibanserin (BIMT 17) has been described as a 5‐HT1A agonist with preferential affinity for postsynaptic 5‐HT1A receptors and as… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)